News Releases

SAN JOSE, CA, Jan 14, 2025: Lykos Therapeutics (“Lykos”), a company dedicated to transforming mental health care, announced today changes to its board of directors. These transitions come as...

Last week a team from Lykos Therapeutics led by new interim CEO, Michael Mullette, and new Chief Medical Officer, Dr. David Hough, had a productive meeting with the FDA regarding next steps in...

Amy Emerson, Lykos' founding leader, stepping down as CEO Pharma veteran and Lykos Chief Operating Officer Michael Mullette appointed as interim CEO Dr. David Hough named Chief Medical Officer SAN...

- Pharmaceutical industry veteran and former Janssen executive Dr. David Hough appointed senior medical advisor to oversee clinical and regulatory - Lykos to significantly reduce workforce,...

U.S. Food and Drug Administration requests additional Phase 3 study Issues raised in CRL echo those discussed in FDA Advisory Committee hearing The Company intends to pursue all available...

Company launching independent advisory board to inform key elements of a potential commercial launch, including therapy training, ethics and healthcare integration Company plans to work with...

Earlier today, the Institute for Clinical and Economic Review (ICER) shared its Final Evidence Report on Midomafetamine-Assisted Psychotherapy for Post-Traumatic Stress Disorder (PTSD).1 Lykos...

Dear Colleagues, As you know, Lykos is entering the final stages of a multi-year effort to study and apply for approval from the U.S. Food and Drug Administration (FDA) for midomafetamine (MDMA)...

Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the outcome of the U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory...

Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective...